| 1 |
张庆红，姚咏明. 严重脓毒症与免疫功能障碍[J]. 医学与哲学, 2014, 35(2):18-22.
|
| 2 |
Angus DC. van der Poll T: Severe sepsis and septic shock[J]. N Engl J Med, 2013, 369:840-851.
|
| 3 |
刘大为. Sepsis-3还告诉了我们什么? [J] 中华危重病急救医学, 2017, 29(2):97-98.
|
| 4 |
Pisetsky DS.The origin and properties of extracellular DNA: From PAMP to DAMP[J]. Clin Immunol, 2012, 144:32-40.
|
| 5 |
Boomer JS, Green JM. Hotchkiss RS: The changing immune system in sepsis[J]. Is individualized immuno-modulatory therapy the answer Virulence, 2014, 5:45-56.
|
| 6 |
Hotchkiss RS. Karl IE: The pathophysiology and treatment of sepsis[J]. N Engl J Med, 2003, 348:138-150.
|
| 7 |
Kumar A.Kethireddy S: Emerging concepts in optimizing antimicrobial therapy of septic shock: Speed is life but a hammer helps too[J]. Crit Care, 2013, 17:104.
|
| 8 |
Martin GS, Mannino DM, Eaton S. The epidemiology of sepsis in the United States from 1979 through 2000[J]. N Engl J Med, 2003, 348:1546-1554.
|
| 9 |
Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure[J]. JAMA, 2011, 306:2594-2605.
|
| 10 |
Hall MW, Knatz NL, Vetterly C, et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome[J]. Intensive Care Med, 2011, 37:525-532.
|
| 11 |
Otto GP, Sossdorf M, Claus RA, et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate[J]. Crit Care, 2011, 15:R183.
|
| 12 |
van Vught LA, Klein Klouwenberg PM, Spitoni C, et al.MARS Consortium: Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis[J]. JAMA, 2016, 315:1469-1479.
|
| 13 |
Angus DC: The search for effective therapy for sepsis: Back to the drawing board? [J] JAMA, 2011, 306:2614-2615.
|
| 14 |
Cohen J, Opal S, Calandra T. Sepsis studies need new direction[J]. Lancet Infect Dis, 2012, 12:503-505.
|
| 15 |
Curley GF, Hayes M, Ansari B, et al. Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat[J]. Thorax, 2012, 67:496-501.
|
| 16 |
Curley GF, Ansari B, Hayes M, et al.Effects of intratracheal mesenchymal stromal cell therapy during recovery and resolution after ventilator-induced lung injury[J]. ANESTHESIOLOGY, 2013, 118:924-932.
|
| 17 |
Hayes M, Masterson C, Devaney J, et al. Therapeutic efficacy of human mesenchymal stromal cells in the repair of established ventilator-induced lung injury in the rat[J]. ANESTHESIOLOGY, 2015, 122:363-373.
|
| 18 |
Krasnodembskaya A, Song Y, Fang X, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37 Stem Cells[J]. 2010, 28:2229-2238.
|
| 19 |
Gupta N, Su X, Popov B,et al. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin induced acute lung injury in mice J[J]. Immunol, 2007, 179:1855-1863.
|
| 20 |
Lee JW FX, Gupta N, Serikov V, et al. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci USA, 2009, 106:6.
|
| 21 |
Wilson JG, Liu KD, Zhuo H, et al. Matthay MA: Mesenchymal stem (stromal) cells for treatment of ARDS: A phase 1 clinical trial[J]. Lancet Respir Med, 2015, 3:24-32.
|
| 22 |
Zhu YG FX, Abbott J, Fang XH, et al. Lee JW: Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxininduced acute lung injury in mice[J]. Stem Cells, 2014, 32:10.
|
| 23 |
Gupta N, Krasnodembskaya A, Kapetanaki M, et al. Matthay MA: Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia colipneumonia[J]. Thorax, 2012, 67:533-539.
|
| 24 |
Shalaby SM, El-Shal AS, Abd-Allah SH, et al. Abdelazim S: Mesenchymal stromal cell injection protects against oxidative stress in Escherichia coli-induced acute lung injury in mice[J]. Cytotherapy, 2014, 16:764-775.
|
| 25 |
Devaney J, Horie S, Masterson C, et al. Laffey JG: Human mesenchymal stromal cells decrease the severity of acute lung injury induced by E[J]. coli in the rat. Thorax, 2015, 70:625-635.
|
| 26 |
Krasnodembskaya A, Samarani G, Song Y, et al. Matthay MA: Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes[J]. Am J Physiol Lung Cell Mol Physiol, 2012, 302:L1003-1013.
|
| 27 |
Sutton MT, Fletcher D, Ghosh SK, et al. Bonfield TL: Antimicrobial properties of mesenchymal stem cells: Therapeutic potential for cystic fibrosis infection, and treatment[J]. Stem Cells Int, 2016, 5303048.
|
| 28 |
Yuan Y, Lin S, Guo N, et al. Ye H: Marrow mesenchymal stromal cells reduce methicillin-resistant Staphylococcus aureus infection in rat models[J]. Cytotherapy, 2014, 16:56-63.
|
| 29 |
Guerra AD, Cantu DA, Vecchi JT, et al. Kao WJ: Mesenchymal stromal/stem cell and minocycline-loaded hydrogels inhibit the growth of staphylococcus aureus that evades immunomodulation of blood-derived leukocytes[J]. AAPS J, 2015, 17:620-630.
|
| 30 |
Monsel A, Zhu YG, Gennai S, et al. Lee JW: Therapeutic effects of human mesenchymal stem cell-derived microvesicles in severe pneumonia in mice[J]. Am J Respir Crit Care Med, 2015, 192:324-336.
|
| 31 |
Mei SH, Haitsma JJ, Dos Santos CC, et al. Stewart DJ: Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis[J]. Am J Respir Crit Care Med, 2010, 182:1047-1057.
|
| 32 |
Németh K, Leelahavanichkul A, Yuen PS, et al. Mezey E: Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin
|
| 33 |
dos Santos CC, Murthy S, Hu P, et al. Liles WC: Network analysis of transcriptional responses induced by mesenchymal stem cell treatment of experimental sepsis[J]. Am J Pathol, 2012, 181:1681-1692.
|
| 34 |
Weil BR, Herrmann JL, Abarbanell AM, et al. Meldrum DR: Intravenous infusion of mesenchymal stem cells is associated with improved myocardial function during endotoxemia[J]. Shock, 2011, 36:235-241.
|
| 35 |
Martinon F, Burns K. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta[J]. Mol Cell, 2002, 10:417-426.
|
| 36 |
Miao CM, Jiang XW, He K, et al. Bone marrow stromal cells attenuate LPS-induced mouse acute liver injury via the prostaglandin E 2-dependent repression of the NLRP3 inflammasome in Kupffer cells[J]. Immunol Lett, 2016, 179:102-113.
|
| 37 |
Kolaczkowska E,. Kubes P: Neutrophil recruitment and function in health and inflammation[J]. Nat Rev Immunol, 2013, 13:159-175.
|
| 38 |
Mei SH, Haitsma JJ, Dos Santos CC, et al.Stewart DJ: Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis[J]. Am J Respir Crit Care Med, 2010, 182:1047-1057.
|
| 39 |
Chao YH, Wu HP, Wu KH, et al. Fu YC: An increase in CD3＋CD4＋CD25＋ regulatory T cells after administration of umbilical cord-derived mesenchymal stem cells during sepsis[J]. PLoS One, 2014, 9:e110338.
|
| 40 |
Ghannam S, Pène J, Moquet-Torcy G, et al. Yssel H: Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype[J]. J Immunol, 2010, 185:302-312.
|
| 41 |
Duffy MM, Ritter T, Ceredig R.Griffin MD: Mesenchymal stem cell effects on T-cell effector pathways[J]. Stem Cell Res Ther, 2011, 2:34.
|
| 42 |
Krampera M, Cosmi L, Angeli R, et al.Annunziato F: Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells[J]. Stem Cells, 2006, 24:386-398.
|
| 43 |
DelaRosa O, Sánchez-Correa B, Morgado S, et al.Casado JG: Human adipose-derived stem cells impair natural killer cell function and exhibit low susceptibility to natural killermediated lysis[J]. Stem Cells Dev, 2012, 21:1333-1343.
|
| 44 |
Belkaid Y. Tarbell K: Regulatory T cells in the control of host-microorganism interactions[J]. Annu Rev Immunol, 2009, 27:551-589.
|
| 45 |
Sun J, Han ZB, Liao W, et al. Han ZC: Intrapulmonary delivery of human umbilical cord mesenchymal stem cells attenuates acute lung injury by expanding CD4＋CD25＋ Forkhead Boxp3 (FOXP3)＋ regulatory T cells and balancing anti- and pro-inflammatory factors[J].Cell Physiol Biochem, 2011, 27:587-596.
|
| 46 |
Heuer JG, Zhang T, Zhao J, et al. Na S: Adoptive transfer of in vitro-stimulated CD4＋CD25＋ regulatory T cells increases bacterial clearance and improves survival in polymicrobial sepsis[J]. J Immunol, 2005, 174:7141-7146.
|
| 47 |
Xu G, Zhang L, Ren G, et al. Shi Y: Immunosuppressive properties of cloned bone marrow mesenchymal stem cells[J]. Cell Res, 2007, 17:240-248.
|
| 48 |
Islam MN, Das SR, Emin MT, et al. Bhattacharya J: Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury[J]. Nat Med, 2012, 18:759-765.
|